Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders

Explore clinical trials studying Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders. Study availability and eligibility vary by location and protocol.

3 public trials 2 recruiting studies

Refine in advanced search Browse all conditions

Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders trial results

Recruiting

French Registry for Monitoring Pregnancies for Multiple Sclerosis

NCT03900221

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Behavior, +17 more
Locations: Chu D'Amiens Amiens, France

Centre Hospitalier Annecy Genevois Annecy, France

Centre Hospitalier d'Avignon Avignon, France

Hopital Jean Minjoz Besançon, France

View all 48 locations

View Trial Details

Recruiting

Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders

NCT06617962

Conditions: Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders
Locations: Huashan Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Not Yet Recruiting

Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool

NCT07704294

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Cranial Nerve Diseases, +25 more
Locations: Moorfields Eye Hospital NHS Foundation Trust London, United Kingdom

Guy's and St Thomas' NHS Foundation Trust London, United Kingdom

King's College Hospital NHS Foundation Trust London, United Kingdom

View Trial Details

Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders

Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders trial results

French Registry for Monitoring Pregnancies for Multiple Sclerosis

Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders

Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool

Related conditions